- NewsCategory：
- All Company news Industry news
common105One result
-
0912
I-Mab Biopharma and Junshi♣₹ Biosciences Announce Collaboration ↕★∑§to Evaluate TJD5 in Combination with Toripalimλ<ab
WEDNESDAY, SEPTEMBER 11, 2019I-Mab Biopharma ¥(I-Mab), a China and U.S.-bΩ ¶ased clinical stage biopharmaceutical company↓∏♦Ω exclusively focused on the dδ¶iscovery and development of potential firs÷€♦t-in-class and best-in-class biologics in imβ✘muno-oncology and autoimmune diseases announλ✘↕↑ces the signing of a ™≈↓£collaboration agreement with Shanghai Juns≤σ©hi Biosciences Co., Ltd (Junshi Biosciences), aσ↔≈↑n innovation-driven biophar₹★✘maceutical company to evaluate§¥ the combination therapy of I-♠δMab's TJD5, a proprietary innovative CD73 antibσ¥'ody with Junshi Biosciences₩>↔' Toripalimab (Trade name: Tuoyi), a recombαα£inant humanized anti§€-PD-1 monoclonal antibod §y in patients with can"₹ ₽cers in China.Dr. Jingwu Zang, Fo✔≥ under and Chairman of I-Mab, comment÷← ®ed, "TJD5 is an innovative CD73 antibody withα™₹ best-in-class potential that has ente★™ red into Phase I trial in the US. We are ™↕®↕very pleased to collaborate •§with Junshi to explore t ↑he clinical synergies witπ™←h Toripalimab which is an innovative>ε drug with distinctive treatment advantages&↕¶. We are looking forward to br®§inging more clinical benefits to patients a₽≈cross various cancer types."Dr. N $ing Li, CEO of Junshi απ≠φBiosciences, commented, "As an anti multi- ©♦tumor drug, toripalimab has shown good s→γ¥afety and efficacy in clinical trials with mono↔∏™ and combination therapy. We believe, through"≠♥≤ the cooperation with I-Mab, we coul<₹☆₽d continue to explore the c''ombination potential of toripalimab and innovativ•♣e drugs to improve the outcomes of immune£®-oncology therapy, lightening hop¶¥"e for more patients.2019 Asia-pacific≥→• pharma IP Leader Summit: ht$≈€tp://en.zenseegroup.com/p•β'/510934/ will be held in&n↔☆bsp;Beijing on Nov→₽βember 14-15, and will attract<¥¥ more than 500 industry experts from dome≤₩πstic and foreign pharλ±↔∑maceutical companies, biotechnology companies<♠↑<, governments, associatio∞↕ns, law firms, intellectual property agents₹>♦ and other companies to attend.Official re♥↕gistration and consultat♦♣δ ion channels:Contact：AnnPhone: 021-65650€π✘305Email：Marketing@zenseegroup.comhttp://en.z☆↓enseegroup.com/p/510934/ -
0916
Hansen Pharmaceuticals and Atomwise Launφ™λ≤ch Strategic Collaboration on Artificial Intelli™¥πgence Drug Discovery in Multδ₹₽✔iple Therapeutic Areas
China's leading biopha±¥rmaceutical company Hansoh Pharmaceuticalγπ☆₩ Group Company Limited (" Hansen ™₹γPharmaceutical ") and drug d×< ≠iscovery artificial '€↔<intelligence (AI) Atomwise, Inc. ("®✘ Atomwise ") , a leader in the fiel©$∏ d, announced a collaborative design a >nd discovery of potential drug candidates₹↕ for up to 11 unexposed target proteins in a var☆∞≤♦iety of therapeutic areas.Atomwise and Hansen P↕"harmaceutical's scientific&"✔ team will work closely toπ≤♣←gether in these proj¶>ects. The combination of λ§complementary expertise and technology is e∏₩₹♥xpected to significantl∑™♣©y increase success and ¥★∞reduce timelines for dφ♦ rug discovery and clinical development.Dr. Lu ¥↓Ω₩Aifeng, President of Jiangsu Hans←←≥≤oh Pharmaceutical Gro♣↑'up Co., Ltd., said: Hansen Pharmaceutical ¶↕is committed to using AI technology ≈ ππto innovate and develop ±diverse small molecules in the field of canα↔<$cer and other therapeutics.®$¥ Atomwise is the right partner for ↕ Hansen Pharmaceuticals. We are very impressed w♦←∏φith Atomwise's AI platform, capabil✔Ωities and team. We believe that t←$he two companies will hav• βe an excellent opportunity t→δ≤o develop similar and best-in-class ther£ apeutic drugs. ."Dr. Abraham H☆→® eifets, CEO of Atomwise, said: "We are veφαry excited to work with Hansen Pharmaceutical, C₹λhina's leading biopharmac ♥π§eutical company. Hansen Pharmaceuticals and we al€∑l have strong commitment to innovation and a co↓ ©mmon mission to influence the health of patient§©≤★s worldwide. ."The world-class AI p≠®÷latform for Atomwise s≥εtructured drug desig≤±✔n will guide efforts in hit d >iscovery, accidental discovery to hit-α£∞to-lead selection, and optimizatδλion of lead compounds. Hansen Pharmaceuticals is coε≈αmmitted to biological testing and pharma♦λπ✔ceutical chemistry, as weΩ¥ll as leading subsequent preclinical and cl∞☆inical development activities.Under the terms ¶βof the partnership, Ato>>∑mwise will receive undisclosed technology ☆ royalties, optional royal≥ ∞ties, royalties, and subcontracting "σauthorizations or revenue generated ₽∞↕from the sale of the derivative assets. Based on →•₽the historical average turnover of small mo "₹§lecule drugs, the potential total value₽" ♣ of all successful projects with Atomwise's tr↕φ<ansaction may exceed∞₽≠ potential selling drugs. Hanson Pharm★™≈£aceuticals will receive development an♦γd commercialization rights in all fields and g ÷eographies.2019 Asia-pacific pharma IP Leade✘÷↑r Summit: http://en.zenseegroup.com/p/51093✘$≤4/will be held in Beijing on&β≥→πnbsp;November 14-15, and will attract more th≠∏•an 500 industry experts from dome§≈stic and foreign pharmaceutical companies, b &±iotechnology companies, governmentλ ←s, associations, law firms, intellεαectual property agents and o←→ther companies to attend.Official regi✘↓₹stration and consultation channels:Contact：AnnPh'βone: 021-65650305Email：Marketing@zenseegr¥₹oup.comhttp://en.zenseegroup.com/p/510934/σ✘§↔ -
0917
Akari Therapeutics’ Nomacopan G♠€ranted U.S. Orphan Dλ←rug Designation for Bullous Pemphigoid
Akari Therapeutics, Plc, a biΩ₽opharmaceutical company focused on ☆ σinnovative therapeutεσ≠ics to treat orphan autoimmune and inflammatoγ©ry diseases where the complement (C5) and/or leu™¥$≥kotriene (LTB4) systems are♣$ implicated, today announced t ≠☆hat the U.S. Food and Drug Admi≈♥nistration (FDA) has grant★↔ed orphan drug designation foγ←r nomacopan for the treatment of b≠λ∑ullous pemphigoid (BP).“BP, a severe bli♥ σstering skin condition with no approε♥★ved treatments, is an exciting theε✔φrapeutic target for our lead dru¥≤g candidate, nomacopan§π. It is also a disease of increasing prevalence λ↑due to an aging population and improving σ∑"diagnosis,” said Clive Richardson, ♣ ♠Chief Executive Office ☆δΩr of Akari Therapeutics. “Orphan drug desΩε"ignation for nomacopan≥> is a major step forward for the progrσ₹✔am, positioning nomacopan for eligi↑"bility for an additional seven yea✘←rs of marketing exclusivity✔ in BP if nomacopan i¶∑Ωs approved by the FDA. ♣ ≈This news is in addition to the recent orphan dr↔₩↕>ug designation recei ™σ±ved for our HSCT-TMA program.”Th$•e Company plans to release new sa♣™φfety and efficacy data from an ongoing Phase I"β£≠I trial with nomacopan in patients with BP×±↑ at an oral presentaε₹tion by Dr. Christian Ω∑€Sadik at the 28th European Academy of Derma₩→♦¶tology and Venereology (EAD↔α♦©V) Congress on October 10,♥σ 2019. In August, the Company ↔≥•δannounced new data demonstrating the synλ₹Ωergistic benefits of nomacopan’s dua₹®∞l C5 and LTB4 inhibitory activity in pemphigoid §±disease, generated by Dr. Christi "σan Sadik’s group at University of Lubeck, ≥π"Germany, and published in the August 2019 eⱕdition of JCI Insight<" [link].Orphan drug ←↕★designation by the FDA is gr✘∞anted to promote the ₹★ ÷development of drugs that tar♠♠get conditions affecting 200,000 or fewer U.S. p∏πatients annually and that are expected to ↔φprovide significant therapeutic advantage over π<©existing treatments. Orphan desi§★≥gnation qualifies Akari $≥♦for various benefits, including sev♣•en years of market exclusivity following marββketing approval, tax™' credits on U.S. clinical trials, eli≈☆gibility for orphan drug grants, and a w∏♥<aiver of certain administrative feγ♥es.2019 Asia-pacific pharma ∞λIP Leader Summit:http://en.zenseegroup.com/p/5109→₽34/will be held in&nbsπ>✔↑p;Beijing on&nbε♠♥¥sp;November 14-15, an₩←d will attract more than 500 induγ∞♥>stry experts from domestic and foreign pharmaceut ≤ical companies, biotech♠>nology companies, governments, associati↓$♠ons, law firms, intellectual property age↑βnts and other companies to attend.Official regis α©εtration and consultation channels:Cont♥¶act：AnnPhone: 021-6565030×✘Ω5Email：Marketing@zenseegroupσ∏.comhttp://en.zenseegroup.com/p/510934/ -
0918
Hansoh Pharma and Atoγ ÷αmwise start strategic collaboration on AI α≠drug discovery for multiple therapeutic areaελs
Major Chinese biopharmaceutica×∏§l company Hansoh Pha≥ ←πrmaceutical Group Com✘≥π£pany Limited (Hanmori Pharmaceut¥♥φ$ical Group Co., Ltd., Hanso Pharmaceutical) andλ÷↕ AI ) Atomwise, Inc., a leader in the fi®'eld, announced the collaboration. T♠§ ©he purpose of the collaboration© is to design and di✘απscover potential drug candidates for a total of Ω¥11 private target pro£>§teins in multiple therapeutic areas.Atom¥≥'Ωwise and Hansoh Pharma scientific teams work closβ≤ ely together in each program. The combination of∞" complementary expertise and technology εσhas the potential to dramaticallyπ≥ increase success rates and shorten sch↔₹ε<edules in drug discover✘♦y and clinical development.Dr. Aifeng<≈< Lyu, President of Jiangsu Han₹•soh Pharmaceutical Group Ω∞Co., Ltd., a subsidiary of Hansoh£§ Pharma, said: “Atomwise is the best α↓partner for Hansoh Pharma to use AI technology t✘€ →o innovate and create diverse small molec₽✘"₩ule pipelines in oncology and other therapeutic a>• ±reas. I am very impressed with the team and Ω↑I believe that working together wil π÷l provide a special opportunity to deveγ↔☆lop first-in-class and best-in-→αclass therapeutics. "Dr.↓÷ε Abraham Heifets, CEO of§≠↑ Atomwise, said: “It is a¶₩↑π great pleasure for us to par©™tner with Chinese biopharmaceutical giant Hansoh "׶Pharma. Hansoh Pharma shares ou'∞r strong commitment to innovation and our mi≥₩ssion to influence patient healtΩ¥♦h globally.”Atomwise'¶ ÷>s world-class AI platform for structu↓®re-based drug design ≤∑¶←leads the way in finding hit com€♦₽pounds, selecting lea©±→d compounds from hit compounds,& ₽÷ and optimizing lead compounds. Hansoh Pharma wi©ll contribute in its capacity in biolog∏₩ical assays and medicinal chemistry, ×♣and will lead the subsequent precl>♥™πinical and clinical ≥£∑&development.Subject to the teλΩrms of the collaboration, Atomwise will±α∏ receive revenue based on private technology fee≠✘♣s, option exercise fees, royalt☆₽∏ies, and sublicenses and sales of≈∑₽ assets created under the collaboration. B ±ased on historical average sales of small molecu≥'♣le drugs, the overall potential valuγγe of this transaction for Atomwise may exceed < ★♦the potential value of a hit drug if al φ↑l projects succeed. Hanso♠±h Pharma receives development and commerciali zation rights in all fields and regions.2019 Asi a-pacific pharma IP Leader Summit: http✔₩☆://en.zenseegroup.com/p/510934/©•will be held in Beijing &n∑ ↕bsp;on November 14-15, and wi♠≤£∏ll attract more than 500 in↓↓dustry experts from do☆×mestic and foreign pharmaceutical cλπ♥ompanies, biotechnology companies, gove©$±≠rnments, associations,₩σ✔ law firms, intellectual property agentπ¥±s and other companies to attend.Official <↕registration and consultation channelφ$ ↓s:Contact：AnnPhone: 021-65650305Email：Ma↔δ rketing@zenseegroup.comhttp://en¶φ ☆.zenseegroup.com/p/5109☆ 34/ -
0919
IBio’s Collaboration with So© uth Africa’s AzarGen Biotechnologie•♠s Advances to Next Stage
iBio, Inc. today announced that it has entered i€≠nto the initial Stateme±γnt of Work (“SOW1”) under its Memorandum of ®±Understanding (“MOU”) with Azar•× λGen Biotechnologies (Pty.) Ltd. (“A₹±§♥zarGen”).Following iBio’s succes©∞sful use of its technologies and ∏∑manufacturing capabilities t✘♦≤o advance the development of AzarGen’s suφγ ×rfactant protein therapeutic♦✘¶ through an initial assessment of production fe↓©asibility, in May 2017, the two compa<¥©nies expanded their co✘llaboration by initiating the development∞§♠ of a plant-made ritux♠≥imab for the South African market under the MOU.P™•♦φursuant to the SOW1, iBio wil§☆↓l manufacture research quantities of a p★ ✔lant-made rituximab for AzarGe¶→β↔n using iBio’s proprietary FastPharming™ Systδγ®Ωem. Following batch production, the drug productβσ candidate will undergo testing via iBio ♥♥CDMO’s bioanalytical services.“A•<↕fter demonstrating the success of our platform ∏through our opening project with AzarGen, we ↑♠are now advancing to t ε☆he next stage of the two companies’ collabo∞ ration,” commented Robert B. Kay, iBio’s Chai✔™♦♠rman and CEO. “We look forwσλ§ard to helping AzarGen develop a plant-based, bi±←$✘o-similar rituximab product for t★✘₹he South African market.”“The earlyλ< success in combining iBio’s and AzarGen's advan™"πced genetic engineering₩$βγ and synthetic biology technα←★±iques in plants really empowered us to ≈∏↔♣evolve our business plans and γ↓$product priorities to initiate deσ€♥velopment of a biosimilar version of rituximab,” €≤βsaid Dr. Mauritz Venter, CEO "<←of AzarGen. “As we contiλ nue to move toward the initi'₽λation of advanced pre-clinical acti<¶♠vities, we are confident that iB÷₽io CDMO is ideally suited to provide us with the★₽$α requisite long-term proc₹βess development and cGMP manu×∑facturing support. We are exci ≠♠ted to take this important step f♥£orward in advancing this program±↑≈. Focusing on accessibili$¥ty and affordability of biological med₽↕icine for the African continent, we look ©<<©forward to initiating addition→©al projects with iBio as we progress.”Rituxλγ☆™imab was first appro♥≥≈ved by the U.S. Food and Drug Administration i'↔©σn 1997 for treatment of certain φπB cell non-Hodgkin lymphomas. Sinc↔≠→Ωe that time, its clinical uses h✘&ave expanded to encompass tr¥φφ₹eatment of chronic lymphocytic leukemia, as ™€ well as a range of auto Ω♦&immune diseases, including cer♣'εtain types of rheumatoid artβ™hritis. Rituximab has been ∏placed on the World Health Orga≤ nization’s List of Essential Medicines and it wa σβs ranked as one of the world’s top-10 selling pha★≤rmaceuticals in 2018.2019 Asia-pacifi"÷↑c pharma IP Leader Summit: http://en.z''→>enseegroup.com/p/404716/&n"≥bsp;will be held in&nbs∏"p;Beijing on November 14-15, aΩ<£&nd will attract more than 500 industry expertsε≥ from domestic and foreign p¶ α☆harmaceutical companies, biotechnology →↕₽companies, governments, association÷≠s, law firms, intellectual property agents and ot÷αα×her companies to attend.Official>λβ¥ registration and consultation channels:γ¶'Contact：AnnPhone: 021-65650305Email€®"★：Marketing@zenseegroup.comhttp×←♣:/forms/vi ∑∑ew/22113/
Contact Us
Zensee_Daystar online
© 2011-2016